2025 ESMO Highlights: Transformative Trends in Oncology
Over 3,000 abstracts were presented at ESMO 2025, with 790 identified as relevant to Beacon Oncology. Of these, more than 95% focused on clinical trials.
Key Highlights Include:
- An overview of the clinical trial landscape from ESMO 2025, covering key drugs, targets, and indications
- Insights on the continued dominance of checkpoint inhibitors and ADCs across oncology
- Key updates redefining first-line treatment strategies in lung and breast cancer
You May Also Be Interested In…
Learn More About Oncology
- The Most Comprehensive Way to Search the Oncology Drug Development Landscape: Unique search ontologies based on Oncology drug and trial characteristics
- Market Leading Approach to Oncology Preclinical & Clinical Data Curation: Manual curation of key Oncology research and development data points by Oncology research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Oncology company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
